Research Paper Volume 12, Issue 14 pp 14556—14568

TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy

Figure 3. Stratification subgroup analysis of the relationship between overall survival and TP53 mutation status in immunotherapy-treated NSCLC patients of the MSK-IMPACT cohort with low or high TMB. (A) Kaplan-Meier survival curve analysis shows the OS of NSCLC patients in the MSK-IMPACT cohort divided into four subgroups, namely TP53 mutations and high TMB (n=61), TP53 wildtype and high TMB (n=9), TP53 mutations and low TMB (n=156), and TP53 wildtype and low TMB (n=124). (B) Kaplan Meier survival curve analysis shows the OS of NSCLC patients with TP53 mutations and low TMB (median OS=7 months) compared to NSCLC patients with wild-type TP53 and low TMB (median OS=13 months). (C) Kaplan Meier survival curve analysis shows the OS of NSCLC patients with high TMB irrespective of TP53 mutation, TP53 truncating mutations plus low TMB, TP53 non-truncating mutations plus low TMB, and wildtype TP53 plus low TMB. As shown, NSCLC patients with TP53 truncating mutations plus low TMB shows the lowest overall survival compared to other groups.